Search This Blog

Thursday, September 7, 2023

INOVIO Breakthrough Therapy Designation for Treatment of Recurrent Respiratory Papillomatosis

 Designation based on clinical evidence indicating INO-3107 may demonstrate substantial improvement over existing therapies

• First Breakthrough Therapy designation for an INOVIO DNA medicine candidate


https://finance.yahoo.com/news/inovio-announces-u-fda-breakthrough-120000300.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.